Clinical Updates – Page 4

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates Wellness & Lifestyle

Pramipexole Augmentation in Treatment-Resistant Unipolar Depression: A UK Multicentre Randomised Trial

By MedXY 08/02/2025

A UK multicentre, double-blind, placebo-controlled trial demonstrates that pramipexole augmentation at 2.5 mg reduces depressive symptoms in treatment-resistant unipolar depression at 12 weeks, with some adverse effects noted, supporting its clinical utility.

Clinical Updates Wellness & Lifestyle

Functional MRI Brain Activation as a Predictor of Response to TNF Inhibition in Rheumatoid Arthritis: Insights from the PreCePra Phase 3 Study

By MedXY 08/02/2025

A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.

Clinical Updates Wellness & Lifestyle

Sarilumab in Relapsing Polymyalgia Rheumatica: Clinical Efficacy and Patient-Reported Outcomes from Recent Phase 3 Trials

By MedXY 08/02/2025

Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.

Clinical Updates Wellness & Lifestyle

Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials

By MedXY 08/02/2025

Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.

Clinical Updates Wellness & Lifestyle

Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial

By MedXY 08/02/2025

The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.

Clinical Updates Wellness & Lifestyle

Pre-emptive TIPS vs Glue Obliteration for Acute Fundal Variceal Bleeding in Cirrhosis: Key Insights from the GAVAPROSEC Trial

By MedXY 08/02/2025

The GAVAPROSEC trial demonstrates that pre-emptive TIPS significantly reduces 1-year mortality and rebleeding in cirrhotic patients with acute fundal gastric variceal bleeding compared to glue obliteration plus NSBB.

Clinical Updates Wellness & Lifestyle

EASE-CD: A Validated Endoscopic Ulcer Activity Score for Crohn’s Disease—Clinical Utility and Evidence from Randomized Trials

By MedXY 08/02/2025

The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn's disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.

Clinical Updates Wellness & Lifestyle

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

By MedXY 08/02/2025

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.